AngioDynamics (ANGO) Misses Q3 EPS by 4c, Lowers FY15 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Canaccord Genuity are Buyers of AngioDynamics (ANGO) on Weakness
April 10, 2015 9:55 AM EDTCanaccord Genuity analyst Jason Mills lowered his price target on AngioDynamics (NASDAQ: ANGO) to $20.00 (from $22.00) following soft Q3 results but maintained a Buy rating. The firm would be buyers on weakness.
Mills commented, "We would be buyers on weakness associated with soft FQ3 results and downward revision to guidance. On the heels of several consecutive quarters of solid execution, including expanding top-line growth and GM, a confluence of factors negatively impacted the business in F3Q, driving revenue below expectations. A few of these challenges were out of ANGOs control (negative foreign... More
AngioDynamics (ANGO) PT, Estimates Cut at Piper Jaffray Following 'Tough' Qtr
April 10, 2015 7:16 AM EDTPiper Jaffray analyst Thomas Gunderson cut estimates and his price target on Neutral-rated AngioDynamics (NASDAQ: ANGO) to $18 (from $21) following a "tough" quarter.
Gunderson commented, "ANGO reported Q3 (Feb) results that were below ours and consensus expectations; Q4 guidance was also lower than Street... More
AngioDynamics (ANGO), EmboMedics Enter Global Microspheres Licensing Agreement
April 9, 2015 4:10 PM EDTAngioDynamics (NASDAQ: ANGO) announced a worldwide licensing agreement with privately-held EmboMedics Inc., of Minneapolis, Minn., which develops injectable and resorbable microspheres. Embolization is the fastest growing segment in Interventional Radiology, and this newly formed strategic relationship will allow AngioDynamics to leverage the talent and knowledge of its sales team to re-enter the approximately $150 million addressable global embolic market.
"AngioDynamics previously helped to build the embolics market, and with worldwide rights to a margin accretive, truly novel technology, we are poised to emulate that success," said Joseph... More
